Overview
A. Non-small cell lung cancer
1. Evaluation of serum and tissue molecular biologic markers of recurrence in patients with a localize non-small cell lung cancer.
2. Molecular biologic staging of lymph nodes in patients with non-small cell lung cancer.
3. The evaluation of the clonality of metastatic tumors in patients with non-small cell lung cancer.
B. Clinical research activities
1. Creation of a prospective database for the Duke Thoracic Oncology Program.
2. A cost and satisfaction evaluation of thoracoscopy and open thoracotomy in patients.
3. Development of risk associated models of morbidity in patients undergoing general thoracic surgery procedures: The VA Cooperative Surgical Risk Study
4. A member of the Duke Gastrointestinal Malignancy Research Committee, developing esophageal cancer treatment protocols and outcome studies.
1. Evaluation of serum and tissue molecular biologic markers of recurrence in patients with a localize non-small cell lung cancer.
2. Molecular biologic staging of lymph nodes in patients with non-small cell lung cancer.
3. The evaluation of the clonality of metastatic tumors in patients with non-small cell lung cancer.
B. Clinical research activities
1. Creation of a prospective database for the Duke Thoracic Oncology Program.
2. A cost and satisfaction evaluation of thoracoscopy and open thoracotomy in patients.
3. Development of risk associated models of morbidity in patients undergoing general thoracic surgery procedures: The VA Cooperative Surgical Risk Study
4. A member of the Duke Gastrointestinal Malignancy Research Committee, developing esophageal cancer treatment protocols and outcome studies.
Current Appointments & Affiliations
George Barth Geller Distinguished Professor for Research in Cancer
·
2022 - Present
Surgery, Cardiovascular and Thoracic Surgery,
Surgery
Professor of Surgery
·
2003 - Present
Surgery, Cardiovascular and Thoracic Surgery,
Surgery
Professor in Pathology
·
2018 - Present
Pathology,
Clinical Science Departments
Member of the Duke Cancer Institute
·
1987 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
TROPION-Lung12: A phase 3 study of adjuvant datopotamab deruxtecan and rilvegostomig in ctDNA-positive or high-risk pathology stage I non-small cell lung cancer.
Conference J Thorac Cardiovasc Surg · January 2026 BACKGROUND: Five-year disease recurrence rates for patients with stage I non-small cell lung cancer (NSCLC) postsurgery are variable (15%-40%). There is an urgent need for novel biomarker strategies to identify high-risk patients who may benefit from adjuv ... Full text Link to item CiteResponse to Letter to the Editor.
Journal Article J Thorac Oncol · December 2025 Full text Link to item CiteSurgical Outcomes With Neoadjuvant Durvalumab Plus Chemotherapy Followed by Adjuvant Durvalumab in Resectable NSCLC.
Conference J Thorac Oncol · November 2025 INTRODUCTION: In AEGEAN, perioperative durvalumab plus neoadjuvant chemotherapy, versus neoadjuvant chemotherapy alone, significantly improved event-free survival (p = 0.004) and pathologic complete response (p < 0.001; primary end points; modified intenti ... Full text Link to item CiteRecent Grants
AstraZeneca AB / A multicentre, Phase II, single-arm, interventional study of neoadjuvant durvalumab and platinum-based chemotherapy (CT), followed by either surgery and adjuvant durvalumab or chemoradiotherapy (CRT) and consolidation durvalumab
Clinical TrialPrincipal Investigator · Awarded by AstraZeneca AB · 2025 - 2029Stimulating Access to Research in Residency (StARR) - NIAID
Inst. Training Prgm or CMEPrincipal Investigator · Awarded by National Institute of Allergy and Infectious Diseases · 2018 - 2029Duke Research Training Program in Surgical Oncology
Inst. Training Prgm or CMEPrincipal Investigator · Awarded by National Cancer Institute · 2024 - 2029View All Grants
Education, Training & Certifications
University of Virginia ·
1984
M.D.